Comparative Pharmacology
Head-to-head clinical analysis: FLUORODOPA F18 versus PYROLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORODOPA F18 versus PYROLITE.
FLUORODOPA F18 vs PYROLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
Pyrolite is not a recognized pharmaceutical drug. No mechanism of action data available.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
1000 mg orally every 8 hours for 7 days.
None Documented
None Documented
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Terminal half-life: 4.5 hours (range 3.8–5.2). Clinical context: Eliminated rapidly; no accumulation with q6h dosing; dose adjustment needed in CrCl <30 mL/min.
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: 10% as conjugates.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical